What Does Low Pd L1 Expression Mean For Treatment?

If your biopsy report shows low PD-L1 expression, it means your tumor has few of the proteins that some immunotherapy drugs target. This matters because certain checkpoint inhibitor drugs, like pembrolizumab (Keytruda) and nivolumab (Opdivo), work best when PD-L1 levels are high. Low expression does not mean immunotherapy is impossible, but it does mean these drugs are less likely to work on their own. Your doctor will likely weigh other treatment options, including chemotherapy, surgery, radiation, or combination approaches, depending on your specific cancer type and stage.

What Is PD-L1 and Why Does It Matter?

PD-L1 is a protein found on the surface of some cancer cells. It acts like a shield. When immune cells called T-cells approach the tumor, PD-L1 binds to a receptor on those T-cells called PD-1. This binding sends a “stop” signal. The T-cell backs off instead of attacking the cancer.

Immunotherapy drugs called checkpoint inhibitors block this interaction. They stop the PD-L1 protein from binding to PD-1. This removes the brake on the immune system, allowing T-cells to recognize and attack the tumor.

Pathologists measure PD-L1 expression using a test called immunohistochemistry. They stain a tissue sample and estimate what percentage of tumor cells show the protein. The result is reported as a percentage, such as 5% or 60%. Different cancers use different scoring systems, but the core idea is the same: higher percentages mean more of the tumor is positive for PD-L1.

What Does Low PD-L1 Expression Actually Mean?

Low PD-L1 expression generally means that fewer than 1% to 5% of tumor cells display the protein, depending on the scoring system used. Some tests report “TPS” (tumor proportion score), which is the percentage of viable tumor cells with partial or complete membrane staining.

For lung cancer, a TPS below 1% is considered negative. A TPS of 1% to 49% is considered low or weak positive. A TPS of 50% or higher is considered high expression. These cutoffs matter because they directly influence whether a drug is approved for use alone as a first treatment.

Low expression does not mean your immune system cannot fight the cancer. It means the specific mechanism these drugs rely on — blocking PD-L1 — is less likely to be effective. The tumor may have other ways to suppress immunity, or the immune response may be weak for other reasons.

How Does Low PD-L1 Expression Affect Immunotherapy Response?

Studies consistently show that higher PD-L1 expression predicts better response to checkpoint inhibitors. For patients with high expression, these drugs can produce dramatic and durable responses. For patients with low or negative expression, the response rate is lower.

That said, some patients with low PD-L1 expression still respond to immunotherapy. The response is just less predictable. Oncologists do not rely on PD-L1 alone when making treatment decisions.

Other factors matter too. Tumor mutational burden (TMB) measures how many mutations are present in the tumor DNA. Tumors with many mutations often produce abnormal proteins that the immune system can recognize. Microsatellite instability (MSI) is another biomarker. Tumors that are MSI-high often respond well to immunotherapy regardless of PD-L1 status.

Your oncologist may test for these additional biomarkers to get a fuller picture of how your immune system might interact with the tumor.

What Treatment Options Exist for Low PD-L1 Tumors?

For many cancers with low PD-L1 expression, chemotherapy remains a primary treatment. Chemotherapy kills rapidly dividing cells and can shrink tumors even when immunotherapy is less effective.

Combination therapy is another common approach. Some clinical trials have shown that combining chemotherapy with immunotherapy improves outcomes compared to chemotherapy alone, even in patients with low PD-L1 expression. This combination is now a standard option for several cancer types, including non-small cell lung cancer.

Surgery and radiation remain important tools. If the tumor is localized and can be removed, surgery may be curative. Radiation can shrink tumors and may be combined with other treatments.

Targeted therapy is an option when the tumor has specific genetic mutations. For example, lung cancers with EGFR or ALK mutations respond well to targeted pills rather than immunotherapy. Your doctor may order genomic testing to look for these mutations.

The evidence is clear that low PD-L1 expression does not mean you are out of options. It means the treatment strategy needs to be broader and may rely more heavily on chemotherapy or combination approaches.

Does Low PD-L1 Expression Change the Prognosis?

PD-L1 expression is a predictive biomarker, not a prognostic one. This is an important distinction. A predictive biomarker tells you how likely a treatment is to work. A prognostic biomarker tells you about the natural course of the disease.

Low PD-L1 expression does not necessarily mean your cancer is more aggressive. It does not mean your cancer will grow faster or spread sooner. It simply means that one particular class of drugs is less likely to produce a response.

Your overall prognosis depends on many factors: the type of cancer, the stage at diagnosis, your overall health, and how the tumor responds to whatever treatment you receive. No single test result determines your outcome.

Are There Cancers Where PD-L1 Testing Is Less Useful?

PD-L1 testing is not equally informative for every cancer type. In melanoma, for example, immunotherapy is effective even in many patients with low PD-L1 expression. The FDA approved checkpoint inhibitors for melanoma regardless of PD-L1 status.

In kidney cancer and Hodgkin lymphoma, PD-L1 testing is not routinely required before starting immunotherapy. The response rates are high enough that testing does not change the treatment decision.

In lung cancer, head and neck cancer, and bladder cancer, PD-L1 testing plays a more central role. It helps determine whether immunotherapy alone can be used as first-line treatment or whether chemotherapy should be included.

Your oncologist will interpret the PD-L1 result in the context of your specific cancer type. A low score in one cancer may carry different weight than a low score in another.

Can PD-L1 Expression Change Over Time?

Yes. PD-L1 expression is not a fixed property of a tumor. It can change as the tumor evolves or in response to treatment. A tumor that was PD-L1 low at diagnosis might show higher expression later, or vice versa.

This is one reason doctors may re-biopsy a tumor if it starts growing again after treatment. The new sample can show whether the tumor has changed in ways that affect treatment options.

It is also worth noting that PD-L1 expression can vary within a single tumor. One area might stain positive while another area is negative. A biopsy samples only a small piece of the tumor, so the result is an estimate, not a complete picture.

What Questions Should You Ask Your Doctor?

When you receive a low PD-L1 result, you should ask what it means for your specific situation. Good questions include:

• What percentage exactly was reported, and what scoring system was used?
• Was the tumor tested for other biomarkers like TMB or MSI?
• What treatment options does this result rule in or rule out?
• Is combination therapy an option for my cancer type and stage?
• Should we consider a repeat biopsy if the tumor progresses?

These questions help you understand how the result fits into your broader treatment plan. They also ensure you are not making decisions based on a single number without context.

What Does Low PD-L1 Expression Mean for Clinical Trials?

Low PD-L1 expression does not exclude you from clinical trials. In fact, many trials specifically enroll patients with low or negative PD-L1 expression because this group has fewer standard treatment options.

Researchers are actively studying ways to make immunotherapy work better in PD-L1 low tumors. Some approaches include combining checkpoint inhibitors with other drugs that stimulate the immune system, using different dosing schedules, or pairing immunotherapy with radiation to trigger an immune response.

If you are interested in clinical trials, ask your oncologist whether any are available for your cancer type and biomarker profile. Trial participation is voluntary and can offer access to treatments not yet widely available.